Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Q4 FY2021 earnings call
February 28, 2022 · fiscal period ended 2021-12
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2022-02-28
Management highlights
Pascal Touchon discussed tab-cel's MAA review in Europe and BLA submission plan in US. Tab-cel's CMC development and comparability studies were detailed. ATA188's momentum, including EBV and MS connections, Fast Track designations, EMBOLD Study progress, and upcoming Atara EBV and MS Day were mentioned. Strategic partnership with FUJIFILM Diosynth Biotechnologies was announced. Jakob Dupont talked about ATA188's EBV and MS implications, Phase 1 data, Phase 2 EMBOLD Study interim analysis, CAR T programs including ATA2271's issues and ATA3271's progress, and Atara's allogeneic EBV T-cell platform.
Guidance
Anticipated approval of tab-cel in Q4 2022. Plan to conduct interim analysis for ATA188 EMBOLD Study in Q2 2022. Anticipated IND filing for ATA3271 in fourth quarter of 2021. Update on ATA2271 investigation expected in next several weeks.
Risks
Uncertainty in tab-cel's regulatory approval process with FDA. Potential impact of unexpected preliminary FDA responses. Complexity of investigating fatal serious adverse events in ATA2271 Phase 1 study.
Q&A highlights
Q: Salim Syed asked about ATA188's interim analysis communication, potential partnerships, RMS trial start, and EBV platform for long COVID.
A: Pascal Touchon and Jakob Dupont responded.
Q: Tessa Romero asked about EMA's view on tab-cel comparability and FDA's reasons for not seeing comparability.
A: Pascal Touchon and Jakob Dupont responded.
Q: John Newman asked about ATA188 interim analysis data sharing and tab-cel's alternative paths with FDA.
A: Pascal Touchon and Jakob Dupont responded.
Q: Ernie Rodriguez asked about FDA's change in mind on tab-cel and the study recommendation.
A: Pascal Touchon responded.
Q: Carolina Ibanez asked about ATA2271's cell expansion and 1XX co-stimulatory domain.
A: Jakob Dupont and Pascal Touchon responded.
Q: Tony Butler asked about tab-cel's comparability impact and ATA188's development confidence.
A: Jakob Dupont and Pascal Touchon responded
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-24.00 | $-15.00 | -60.0% | $-23.75 |
| Revenue | $7.5M | $31.4M | -75.9% | $358.2M |
Transcript
February 28, 2022Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.